House Energy and Commerce Committee releases 340B report
The House Energy and Commerce Committee yesterday released a report on the 340B Drug Pricing Program. “The 340B program is an important program that enjoys strong bipartisan support in Congress,” the report says. “The program helps reduce the prices of covered drugs for certain participating entities who, in turn, provide care for patients.” The report, which comes after two years of the committee examining the operation and oversight of the 340B program, includes a number of findings about the program, as well as 12 recommendations.
Related News Articles
Headline
The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect…
Headline
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on…
Headline
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the…